Bausch Health Companies Inc. Stock News

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a confere

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.

The shares of pharma stock Bausch Health Companies Inc (NYSE:BHC) have taken a tumble since their recent April 3 nearly two-year high of $11.46.

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference

Bausch + Lomb Chairman and CEO Brent Saunders joins 'Mad Money' host Jim Cramer to talk earnings.

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street

Bausch Health (BHC) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago.

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.